China Ordered Rare Disease Clinics in Every Province by December and Left Payment Out
- China’s National Health Commission and the State Administration of Traditional Chinese Medicine published a notice on 20 September 2026 directing provincial health authorities to strengthen rare disease prevention and treatment. The document, Medical Administration Letter [2026] No. 305, is dated 14 September.
- By the end of 2026, each of the 31 provincial-level jurisdictions and the Xinjiang Production and Construction Corps must run a rare disease clinic in at least one provincial or higher-level hospital. Every prefecture-level city with more than 3 million people must have one in at least one hospital, and provincial rare disease quality control centres must reach full coverage by the same date.
- The notice extends the National Collaborative Network for rare disease diagnosis and treatment, brings qualified traditional Chinese medicine hospitals into it, and orders training so county and primary care hospitals can identify and refer suspected cases. It calls for standardised gene testing, AI-assisted diagnosis and, where regions have capacity, preconception screening for high-risk groups.
- China has named 207 rare diseases across two national lists, 121 in 2018 and 86 in 2023. A review published in February 2026 counted 223 rare disease drugs marketed in China as of December 2025, 136 of them, or 61.0%, on the National Reimbursement Drug List.
Access read
Every instruction in the notice raises the number of diagnosed patients. None of it addresses what those patients can be prescribed or who pays for it.
- The deadline is 102 days from publication. Clinics in every province and every city above 3 million, plus full provincial quality control coverage, by 31 December. What is being built is a funnel: screening, referral up a hierarchical network, and standardised diagnosis at the top of it.
- The payer did not sign. The notice comes from the health commission and the traditional medicine administration. Reimbursement sits with the National Healthcare Security Administration, which runs the NRDL and, since January 2026, a separate commercial insurance list of 19 high-cost innovative drugs. The document does not mention reimbursement, insurance or pricing.
- Diagnosis is outrunning treatment on the government’s own list. A 2026 policy review found only 37 of the 86 diseases added in 2023 had a drug approved for that indication in China. Standardised diagnosis for the rest produces a confirmed patient with no approved domestic option, and that population is the strongest case any sponsor holding an approval abroad can bring to Chinese regulators.